CD22 and leukemia: Engineered CAR T cells specific for CD22 or CD123 showed similar antitumor activity toward their respective leukemia cell line targets (RAJI and MOLM13 tumor cells, respectively, Fig. 2a, b) regardless of the number of edited features (ΔTRACCAR, ΔTRACCARΔB2M, and ΔTRACCARΔB2MHLAE).